
About HepCVel medicine:
• Hepcvel is a combined medicine used to treat chronic hepatitis C infection. It can also be used in combination with ribavirin for patients with advanced cirrhosis.
• This drug is not recommended for use in patients with a history of hepatitis B infection due to the risk of serious side effects.
• You will usually need this medication every day for 12 or 24 weeks.
• Skipping doses increases the risk of treatment failure. Make sure you take all your doses at the right time.
• It may cause fatigue, dizziness and blurred vision. Do not drive or do anything that requires concentration until you know how it affects you.
Note the dose and overdose when using HepCVel
• Missing dose: take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.
• Overdose: seek emergency medical treatment or contact a doctor in case of an overdose.
Some side effects of HepCVel:
• The following serious adverse reactions are described below and elsewhere in the labeling: severe arrhythmia when Sofosbuvir (Hepcvel) is combined with Amiodarone and another direct HCV antiviral drug.
• If Hepcvel is taken with ribavirin, refer to the ribavirin prescription information for a description of the adverse reactions associated with ribavirin.
Less common adverse reactions have been reported in clinical trials
The following adverse reactions occurred in less than 5% of subjects who did not have cirrhosis or compensated cirrhosis treated with Hepcvel for 12 weeks and included because of a potential causal relationship.
• Rash: In the ASTRAL-1 study, rash occurred in 2% of subjects treated with Hepcvel and 1% of subjects treated with placebo. No serious adverse reactions of the rash occurred and all rashes were mild or moderate.
• Depression: In the ASTRAL-1 study, depressive mood occurred in 1% of subjects treated with Hepcvel and not reported by anyone taking a placebo. No serious adverse reactions of depressive mood occurred and all events were mild or moderate.
Experience on the market
• The following adverse reactions have been identified during the use of Sofosbuvir (Hepcvel). Because post-market responses are voluntarily reported from an uncertain size population, it is not always possible to reliably estimate their frequency or establish a relationship. causality with drug exposure.
• Cardiac disorders: Severe symptomatic bradycardia has been reported in patients receiving amiodarone who started treatment with Sofosbuvir (Hepcvel) in combination with another HCV direct antiviral drug.
Reference source:
- Thuoc hepcvel dieu tri viem gan C hieu qua Gia thuoc hepcvel https://nhathuocgan.com/thuoc-hepcvel-dieu-tri-viem-gan-c/
- Thuoc HepCVel dac tri viem C cong hieu Nha thuoc https:/dieutriung.org/thuoc-hepcvel-tri-viem-gan-c/
- Thuoc HepCVel hoat chat Sofosbuvir 400mg Velpatasvir 100mg https://nhathuocgan.blogspot.com/2019/12/thuoc-hepcvel-hoat-chat-sofosbuvir-velpatasvir.html